<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00752570</url>
  </required_header>
  <id_info>
    <org_study_id>20070307</org_study_id>
    <nct_id>NCT00752570</nct_id>
  </id_info>
  <brief_title>A Phase 2, Randomized, Double Blind, Placebo Controlled Study of AMG 386 in Combination With FOLFIRI in Subjects With Previously Treated Metastatic Colorectal Carcinoma</brief_title>
  <official_title>A Phase 2, Randomized, Double Blind, Placebo Controlled Study of AMG 386 in Combination With FOLFIRI in Subjects With Previously Treated Metastatic Colorectal Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <brief_summary>
    <textblock>
      This clinical trial will compare the efficacy and safety of the combination of AMG 386 and
      FOLFIRI with FOLFIRI alone in second line treatment of metastatic colorectal cancer.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To estimate the treatment effect as measured by progression free survival (PFS) in subjects treated with AMG 386 + FOLFIRI relative to subjects treated with FOLFIRI + placebo.</measure>
    <time_frame>The time frame will be event driven and will occur when 100 subjects have experienced a PFS event (radiographic disease progression or death).</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate other measures of efficacy or clinical response including objective response rate (ORR), duration of response (DOR), overall survival (OS) in subjects treated with AMG 386 + FOLFIRI relative to subjects treated with FOLFIRI + placebo</measure>
    <time_frame>Treatment phase or until disease progression</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate progression free survival and measures of efficacy by KRAS status</measure>
    <time_frame>Treatment phase</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate patient reported outcomes (PROs), relative dose intensity, incidence of anti AMG 386 antibody formation, pharmacokinetics of AMG 386 (Cmax and AUC) and safety (incidence of AEs and significant laboratory changes)</measure>
    <time_frame>Throughout study</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">144</enrollment>
  <condition>Cancer</condition>
  <condition>Carcinoma</condition>
  <condition>Colon Cancer</condition>
  <condition>Colorectal Cancer</condition>
  <condition>Gastrointestinal Cancer</condition>
  <condition>Metastases</condition>
  <condition>Metastatic Cancer</condition>
  <condition>Metastatic Colorectal Cancer</condition>
  <condition>Oncology</condition>
  <condition>Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>AMG 386 placebo QW, FOLFIRI Q2W</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arm 1 : AMG 386 10 mg/kg QW, FOLFIRI Q2W</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AMG 386</intervention_name>
    <description>AMG 386 (10 mg/kg QW) will be administered until subject develops disease progression, clinical progression, unacceptable toxicity, or withdraws consent.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AMG 386 Placebo</intervention_name>
    <description>AMG 386 placebo QW will be administered until subject develops disease progression, clinical progression, unacceptable toxicity, or withdraws consent.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOLFIRI</intervention_name>
    <description>Administration of FOLFIRI chemotherapy will commence on day 1 of each dosing week following the administration of AMG 386.
FOLFIRI Q2W regimen: irinotecan 180 mg/m2 IV over 90 (+-15) minutes on Day 1, leucovorin 400 mg/m2 IV over 2 hrs on Day 1, 5 FU 400mg/m2 IV bolus, followed by 2400 mg/m2 continuous IV infusion over 46 hrs +- 2 hours.
FOLFIRI will be administered until disease progression, FOLFIRI intolerability, death, or study withdrawal by the subject, investigator, or sponsor, whichever occurs earliest.</description>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed adenocarcinoma of the colon or rectum in patients who are
             presenting with metastatic disease

          -  One and only one prior chemotherapy regimen for metastatic disease consisting of the
             combination of a fluoropyrimidine-based chemotherapy and an oxaliplatin-based
             chemotherapy. Prior adjuvant chemotherapy used prior to the onset of metastatic
             disease is permitted

          -  At least one uni dimensionally measurable lesion per modified RECIST criteria. All
             sites of disease must be evaluated &lt;= 28 days before randomization

          -  Radiographically documented disease progression per modified RECIST criteria either
             while receiving or &lt;= 6 months after the last dose of prior chemotherapy regimen for
             metastatic disease

          -  ECOG performance status of 0 or 1

          -  Man or woman &gt;= 18 years of age

          -  Adequate end organ assessments by laboratory studies (hematological and chemistries)

          -  Life expectancy &gt;= 3 months

        Exclusion Criteria:

          -  Exclude subjects with a history of prior malignancy, except:

               -  Malignancy treated with curative intent and with no known active disease present
                  for &gt;= 3 years before enrollment and felt to be at low risk for recurrence by
                  treating physician

               -  Adequately treated non-melanomatous skin cancer or lentigo maligna without
                  evidence of disease

               -  Adequately treated cervical carcinoma in situ without evidence of disease

               -  Prostatic intraepithelial neoplasia without evidence of prostate cancer

          -  Prior irinotecan therapy

          -  Systemic chemotherapy, hormonal therapy, or immunotherapy &lt;= 21 days prior to
             randomization

          -  Experimental or approved proteins/antibodies (eg, bevacizumab) &lt;= 30 days prior to
             randomization

          -  Clinically significant cardiac disease within 12 months prior to randomization,
             including myocardial infarction, unstable angina, grade 2 or greater peripheral
             vascular disease, cerebrovascular accident, transient ischemic attack, congestive
             heart failure, or arrhythmias not controlled by outpatient medication, percutaneous
             transluminal coronary angioplasty/stent

          -  Known allergy or hypersensitivity to irinotecan, 5 FU (known dihydropyrimidine
             dehydrogenase deficiency) or leucovorin

          -  Active inflammatory bowel disease or other bowel disease causing chronic diarrhea
             (defined as &gt;= CTC grade 2 [CTCAE version 3.0])
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <removed_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>France</country>
    <country>India</country>
    <country>Ireland</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 11, 2008</study_first_submitted>
  <study_first_submitted_qc>September 12, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2008</study_first_posted>
  <disposition_first_submitted>July 13, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>July 13, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">August 3, 2015</disposition_first_posted>
  <last_update_submitted>August 14, 2015</last_update_submitted>
  <last_update_submitted_qc>August 14, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 2, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Metastatic Colorectal Cancer</keyword>
  <keyword>colorectal cancer</keyword>
  <keyword>colon cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Colonic Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Gastrointestinal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trebananib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

